OptiBiotix Health plc “USA and the Rest of the World” Stephen O’Hara, CEO

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care announces that, further to the European manufacturing and supply agreement with Sacco S.r.l., announced on 8 March 2017, the Company has entered into a new agreement to cover the USA and the Rest Of the World.

The agreement grants Sacco an exclusive licence to manufacture and supply OptiBiotix’s cholesterol and blood pressure reducing LP(LDL) (R) strain in the US and ROW, in return for 50% of the profit, with a guaranteed cost of manufacture and minimum sales price per kilogramme to secure against discounting. The agreement brings the following benefits:-

1. Access to the US, the worlds largest probiotic market, with an estimated retail value of $7.1 billion per annum

2. Extension of LP(LDL) (R) into dairy applications utilising Sacco’s network in the dairy industry to develop commercial opportunities identified by them in the global $35.5 billion probiotic dairy market

3. Economies of scale, significantly reducing the manufacturing cost of LP(LDL) (R), increasing OptiBiotix’s profitability, and opening up new application opportunities

4. Long-term security of supply with Sacco’s ability to produce at different locations from multiple facilities

5. A commitment from Sacco to support the funding of further developments of LP(LDL) (R), including marketing and human studies, to expand the commercialisation of LP(LDL) (R) into new markets

This agreement is a strategic step to access the US probiotic supplement market, and to extend the opportunities offered by LP(LDL) (R) into dairy applications, with one of the largest and internationally respected supplier of probiotic ingredients. The US is one of the largest and fastest growing probiotic markets in the world, with supplements alone accounting for $2.06 billion sales, with a projected 55% growth to $3.3 billion by 2021. Extension of LP(LDL) (R) into dairy applications widens the commercial opportunity by accessing the $35.5 billion probiotic dairy market.

Market data from ‘TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING THE GLOBAL PROBIOTICS MARKET’ (Euromonitor International June 2017).

Stephen O’Hara, CEO of OptiBiotix, commented: “This new agreement with Sacco significantly extends the scale of the commercial opportunity open to LP(LDL) (R) to new application areas and territories, and reflects growing confidence from both companies in LP(LDL) (R)’s market potential. We chose Sacco as we have been impressed by their ability to introduce LP(LDL) (R) to a global network of distributors and believe extending our partnership with them provides the best opportunity of quickly building revenues and developing LP(LDL) (R) into a global brand. In addition, the ability to supply competitively priced ingredients from a single manufacturer across world markets simplifies the supply chain and contract negotiations with corporate partners.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Optibiotix Health Plc

    More articles like this

    Optibiotix Health Plc

    OptiBiotix Health plc will be presenting research at major USA conference

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced this morning that it will be presenting research data on its microbiome modulators at MicroBiome R&D and Business Collaboration (USA) in San Diego, on 2-3 November 2017. The conference is unique

    Optibiotix Health Plc

    OptiBiotix Plc 3 year supply agreement with Galenicum

    Stephen O’Hara, CEO of OptiBiotix, talks to DirectorsTalk about the 3 year supply agreeement: “We are pleased to announce this agreement with Galenicum which expands sales of LP(LDL) (R) into Latin America and the Middle East

    Optibiotix Health Plc

    OptiBiotix Health PLC Successful launch of products at Supply Side West

    OptiBiotix Health PLC (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, and diabetes has announced the successful launch of its SlimBiome® and LPLDL® products at Supply Side West in Las Vegas, on 27-28 September 2017. The exhibition provided the opportunity to connect with 16,500 ingredient buyers and suppliers from the

    Optibiotix Health Plc

    OptiBiotix Health PLC Invited to present at Expoquimia in Barcelona

    OptiBiotix Health PLC (AIM:OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, has announced it has been invited to present its research and commercial developments at the 18th edition of Expoquimia-World Chemical Summit (‘Expoquimia’) in Barcelona, Spain, on 5 October 2017.   Expoquimia is a multidisciplinary event held triennially

    Optibiotix Health Plc

    OptiBiotix Health PLC Investor evening

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, announces that Stephen O’Hara, CEO of Optibiotix, will be presenting at an investor evening hosted by Turner Pope Investments Ltd (“TPI”). The event will be held on Tuesday 19 September 2017 in Mayfair, London and will commence

    Optibiotix Health Plc

    OptiBiotix Health PLC Milestone with LP-LDL technology

    Stephen O’Hara, Chief Executive Officer at OptiBiotix Health PLC (LON:OPTI) talks to Proactive Investors about the significant milestone with first sales in Germany of a new range of cholesterol-lowering capsules containing their breakthrough LP-LDL technology.

    Optibiotix Health Plc

    OptiBiotix Health plc commercial sales have commenced in Germany

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced this morning that HLH BioPharma Vertriebs GmbH have achieved product registration of LP(LDL) (R) capsules at